DK1345969T3 - Anti-CD28-antistof - Google Patents

Anti-CD28-antistof

Info

Publication number
DK1345969T3
DK1345969T3 DK01995797.6T DK01995797T DK1345969T3 DK 1345969 T3 DK1345969 T3 DK 1345969T3 DK 01995797 T DK01995797 T DK 01995797T DK 1345969 T3 DK1345969 T3 DK 1345969T3
Authority
DK
Denmark
Prior art keywords
antibody
receptor
interaction
blocks
methods
Prior art date
Application number
DK01995797.6T
Other languages
English (en)
Inventor
Jean-Paul Soulillou
Genevieve Laflamme
Bernard Vanhove
Daniel Olive
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of DK1345969T3 publication Critical patent/DK1345969T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK01995797.6T 2000-12-26 2001-12-26 Anti-CD28-antistof DK1345969T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0017025 2000-12-26
PCT/FR2001/004203 WO2002051871A2 (fr) 2000-12-26 2001-12-26 Anticorps anti-cd28

Publications (1)

Publication Number Publication Date
DK1345969T3 true DK1345969T3 (da) 2010-11-29

Family

ID=8858197

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01995797.6T DK1345969T3 (da) 2000-12-26 2001-12-26 Anti-CD28-antistof

Country Status (9)

Country Link
US (1) US7723482B2 (da)
EP (1) EP1345969B1 (da)
JP (1) JP4066166B2 (da)
AT (1) ATE477275T1 (da)
DE (1) DE60142794D1 (da)
DK (1) DK1345969T3 (da)
ES (1) ES2353273T3 (da)
PT (1) PT1345969E (da)
WO (1) WO2002051871A2 (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7531168B2 (en) 2001-02-16 2009-05-12 Genetics Institute Llc Method for downmodulating immune response in type I diabetes
US20080095774A1 (en) * 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
EP2363410B1 (en) * 2002-11-27 2017-10-11 Minerva Biotechnologies Corporation Isoforms of MUC1
DK2363410T3 (da) * 2003-08-26 2018-01-15 Minerva Biotechnologies Corp Isoformer af muc1
US8907065B2 (en) 2006-12-15 2014-12-09 Ablynx N.V. Polypeptides that modulate the interaction between cells of the immune system
MX2011000501A (es) * 2008-07-18 2011-05-23 Squibb Bristol Myers Co Composiciones monovalentes para union a cd28 y metodos de uso.
KR20170091801A (ko) 2008-10-02 2017-08-09 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Ｃｄ86 길항제 다중-표적 결합 단백질
EP2210902A1 (en) * 2009-01-14 2010-07-28 TcL Pharma Recombinant monovalent antibodies
EP2391654B1 (en) 2009-01-28 2015-09-09 Industrial Technology Research Institute Urine and serum biomarkers associated with diabetic nephropathy
FR2951176A1 (fr) 2009-10-09 2011-04-15 Tcl Pharma Ligands monovalents du recepteur cd28 humain
ES2896149T3 (es) * 2010-02-18 2022-02-24 Ose Immunotherapeutics Anticuerpos humanizados anti-CD28
EP2361935A1 (en) * 2010-02-18 2011-08-31 TcL Pharma Anti-CD28 humanized antibodies
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
EP3091032A1 (en) 2015-05-08 2016-11-09 Miltenyi Biotec GmbH Humanized antibody or fragment thereof specific for cd3
RU2755724C2 (ru) 2015-11-18 2021-09-20 Мерк Шарп И Доум Корп. Pd1/ctla4-связывающие вещества
EA201891165A1 (ru) 2015-11-18 2018-11-30 Мерк Шарп И Доум Корп. Молекулы, связывающие pd1 и/или lag3
AU2016355569B2 (en) 2015-11-18 2020-01-02 Merck Sharp & Dohme Llc CTLA4 binders
EP3430058A4 (en) 2016-03-15 2019-10-23 Generon (Shanghai) Corporation Ltd. MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF
US20180206726A1 (en) 2016-12-07 2018-07-26 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
CN112074539A (zh) * 2018-03-15 2020-12-11 比昂生物制剂公司 降低可溶性免疫受体cd28的方法和组合物
CN112638375A (zh) 2018-06-15 2021-04-09 旗舰创业创新五公司 通过后细胞信号传导因子的调节来增加免疫活性
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
CA3108951A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
US11672826B2 (en) 2018-08-30 2023-06-13 HCW Biologics, Inc. Methods of treating aging-related disorders
SG11202101779RA (en) 2018-08-30 2021-03-30 Hcw Biologics Inc Multi-chain chimeric polypeptides and uses thereof
US20210355216A1 (en) 2018-10-05 2021-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale Methods and systems for controlling the agonistic properties of antibody variable domains by light
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
CA3143035A1 (en) 2019-06-21 2020-12-24 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置
WO2021127217A1 (en) 2019-12-17 2021-06-24 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
JP2023519106A (ja) 2020-02-11 2023-05-10 エイチシーダブリュー バイオロジックス インコーポレイテッド クロマトグラフィー樹脂およびその使用
EP4103601A2 (en) 2020-02-11 2022-12-21 HCW Biologics, Inc. Methods of treating age-related and inflammatory diseases
AU2021220196A1 (en) 2020-02-11 2022-08-04 HCW Biologics, Inc. Methods of activating regulatory T cells
JP2023525495A (ja) 2020-04-29 2023-06-16 エイチシーダブリュー バイオロジックス インコーポレイテッド 抗ｃｄ２６タンパク質及びそれらの使用法
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
AU2021283199A1 (en) 2020-06-01 2023-01-05 Immunitybio, Inc. Methods of treating aging-related disorders
WO2021247003A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
KR102607909B1 (ko) 2020-08-19 2023-12-01 젠코어 인코포레이티드 항-cd28 조성물
AU2022246895A1 (en) 2021-03-31 2023-10-19 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
US20240182572A1 (en) 2021-04-09 2024-06-06 Ose Immunotherapeutics Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domains
EP4363059A1 (en) 2021-06-29 2024-05-08 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
AU2023228683A1 (en) 2022-03-02 2024-09-19 Immunitybio, Inc. Method of treating pancreatic cancer
WO2023198851A1 (en) 2022-04-14 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for controlling the tumor cell killing by light
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024077118A2 (en) 2022-10-06 2024-04-11 Bicara Therapeutics Inc. Multispecific proteins and related methods
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
ZA91463B (en) * 1990-01-25 1992-09-30 Bristol Myers Squibb Co Method of activating cytolytic activity of lymphocytes using anti-cd28 antibody
AU7107794A (en) * 1993-06-10 1995-01-03 Regents Of The University Of Michigan, The Cd28 pathway immunosuppression
US5948893A (en) 1996-01-17 1999-09-07 The United States Of America As Represented By The Secretary Of The Navy Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody

Also Published As

Publication number Publication date
WO2002051871A3 (fr) 2002-08-15
US7723482B2 (en) 2010-05-25
ES2353273T3 (es) 2011-02-28
EP1345969B1 (fr) 2010-08-11
PT1345969E (pt) 2010-11-17
ATE477275T1 (de) 2010-08-15
DE60142794D1 (de) 2010-09-23
JP4066166B2 (ja) 2008-03-26
WO2002051871A2 (fr) 2002-07-04
US20080038273A1 (en) 2008-02-14
EP1345969A2 (fr) 2003-09-24
JP2004516034A (ja) 2004-06-03

Similar Documents

Publication Publication Date Title
DK1345969T3 (da) Anti-CD28-antistof
CY1119291T1 (el) Πολυσθενη αντισωματα και χρησεις για αυτα
NO20041325L (no) Substanser
DE69929235D1 (de) Spiro-indole als y5-rezeptor antagonisten
IL195338A0 (en) Optimized fc variants and methods for their generation
DE69918946D1 (de) Rezeptoren für il-18
NO983431D0 (no) Anti-kl°emidler
TR200102029T2 (tr) 1-Heterosiklil ikameli diarilaminler.
CY1112458T1 (el) Ενα αντισωμα ειδικο για διαλυτο baff για χρηση στην αντιμετωπιση του καρκινου
ES2304795T3 (es) Anticuerpos agonistas para el receptor de trombopoyetina y sus usos terapeuticos.
TR200103756T2 (tr) Hümanize anti-ErbB2 antikorları ve anti-ErbB2 antikorlarıyla tedavi.
YU28897A (sh) Biciklicno kondenzovani piridini
NO20063304L (no) Fremgangsmate til a rense FSH
ES2193102T3 (es) Compuestos de imidocromo en sistemas catalizadores para la polimerizacion de olefinas.
DE50311921D1 (de) Mikropartikel mit cd28-spezifischen monoklonalen antikoerpern
TR199800692A3 (tr) Kalsiyum borat üretilmesine mahsus yöntem.
DE69817991D1 (de) Medizinisches gerät
DE69738512D1 (de) Epstein-barr virus type b ctl epitopen
FI980716A0 (fi) Arrangemang i samband med en hydraulvaetskedriven slaganordning, saosom t.ex. i en krossanordning
TR199903187A3 (tr) Kadife kumaslarin yüz-yüze dokunmasi için yöntem.
DK1472433T3 (da) Anordning af ikke-fastklemmende materiale til borekilesystem
BR9806702A (pt) Ferramenta para partir discos de freio
WO2000073345A3 (en) Antibodies specific for mycobacterial polypeptides and uses thereof
ES1045245U (es) Dispositivo de union de perfiles.
CY1116846T1 (el) Pd-1, υποδοχεας για β7-4, και χρησεις γι΄ αυτον τον σκοπο